Fulcrum Therapeutics FULC Stock
Fulcrum Therapeutics Price Chart
Fulcrum Therapeutics FULC Financial and Trading Overview
| Fulcrum Therapeutics stock price | 3.8 USD |
| Previous Close | 3.58 USD |
| Open | 3.63 USD |
| Bid | 2.62 USD x 200 |
| Ask | 4.56 USD x 200 |
| Day's Range | 3.54 - 3.73 USD |
| 52 Week Range | 2.83 - 15.74 USD |
| Volume | 612.15K USD |
| Avg. Volume | 2.52M USD |
| Market Cap | 279.25M USD |
| Beta (5Y Monthly) | 2.997 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.83 USD |
FULC Valuation Measures
| Enterprise Value | -40417820 USD |
| Trailing P/E | N/A |
| Forward P/E | -6.3041496 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.8986006 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.473 |
Trading Information
Fulcrum Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.997 |
| 52-Week Change | -48.56% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 15.74 USD |
| 52 Week Low | 2.83 USD |
| 50-Day Moving Average | 4.1 USD |
| 200-Day Moving Average | 7.95 USD |
FULC Share Statistics
| Avg. Volume (3 month) | 2.52M USD |
| Avg. Daily Volume (10-Days) | 1.28M USD |
| Shares Outstanding | 76.3M |
| Float | 48.08M |
| Short Ratio | 2.24 |
| % Held by Insiders | 3.34% |
| % Held by Institutions | 114.10% |
| Shares Short | 6.91M |
| Short % of Float | 10.50% |
| Short % of Shares Outstanding | 10.36% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.59% |
| Return on Equity (ttm) | -32.37% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -56640000 USD |
| EBITDA | -85396000 USD |
| Net Income Avi to Common (ttm) | -84999000 USD |
| Diluted EPS (ttm) | -1.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 318.84M USD |
| Total Cash Per Share (mrq) | 4.18 USD |
| Total Debt (mrq) | 5.28M USD |
| Total Debt/Equity (mrq) | 1.7 USD |
| Current Ratio (mrq) | 31.351 |
| Book Value Per Share (mrq) | 4.073 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -65777000 USD |
| Levered Free Cash Flow (ttm) | -37373876 USD |
Profile of Fulcrum Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 26 Landsdowne Street |
| ZIP | 02139 |
| Phone | 617 651 8851 |
| Website | https://www.fulcrumtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Fulcrum Therapeutics Stock
What is a current FULC stock price?
Fulcrum Therapeutics FULC stock price today per share is 3.8 USD.
How to purchase Fulcrum Therapeutics stock?
You can buy FULC shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fulcrum Therapeutics?
The stock symbol or ticker of Fulcrum Therapeutics is FULC.
Which industry does the Fulcrum Therapeutics company belong to?
The Fulcrum Therapeutics industry is Biotechnology.
How many shares does Fulcrum Therapeutics have in circulation?
The max supply of Fulcrum Therapeutics shares is 76.3M.
What is Fulcrum Therapeutics Price to Earnings Ratio (PE Ratio)?
Fulcrum Therapeutics PE Ratio is now.
What was Fulcrum Therapeutics earnings per share over the trailing 12 months (TTM)?
Fulcrum Therapeutics EPS is -1.23 USD over the trailing 12 months.
Which sector does the Fulcrum Therapeutics company belong to?
The Fulcrum Therapeutics sector is Healthcare.
Fulcrum Therapeutics FULC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26584.99 USD — |
+2.59
|
8.76B USD — | 26088.04 USD — | 26679.91 USD — | — - | 8.76B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2306.18 USD — |
+3.17
|
— — | 2260.25 USD — | 2312.49 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6578.45 USD — |
+2.29
|
— — | 6447.87 USD — | 6583.71 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1263.73 USD — |
+1.81
|
— — | 1242.12 USD — | 1264.81 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
